as per attachment
VAISHALI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vaishali Pharma's board approved its Q1 FY26 (quarter ended June 30, 2025) unaudited financial results, which received an unqualified limited review report from statutory auditor Raman S. Shah & Associates. Revenue from operations rose to ₹2,374.71 lakhs, up about 31% from ₹1,807.98 lakhs in the same quarter last year. However, profit after tax fell to ₹127.93 lakhs from ₹169.90 lakhs (down ~25%), and EPS dropped to ₹0.10 from ₹0.15, mainly due to higher purchase and other expenses. The board also approved the FY25 Annual Report and Director's Report, and fixed September 22, 2025 as the date for the 18th AGM, with the share transfer books closed from September 15-22, 2025.
Top-line growth is healthy, but shrinking margins and a fall in profit may concern investors in the near term. The stock could see a mixed reaction as strong revenue is offset by weaker profitability.